JP2024519536A - Ｐｘｒを標的とする二官能性ｐｒｏｔａｃ型化合物、同化合物を調製するための方法、及びその治療的使用 - Google Patents

Ｐｘｒを標的とする二官能性ｐｒｏｔａｃ型化合物、同化合物を調製するための方法、及びその治療的使用 Download PDF

Info

Publication number
JP2024519536A
JP2024519536A JP2023572137A JP2023572137A JP2024519536A JP 2024519536 A JP2024519536 A JP 2024519536A JP 2023572137 A JP2023572137 A JP 2023572137A JP 2023572137 A JP2023572137 A JP 2023572137A JP 2024519536 A JP2024519536 A JP 2024519536A
Authority
JP
Japan
Prior art keywords
compound
pxr
group
formula
ligase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519536A5 (https=
Inventor
パスカッシ，ジョン－マルク
パネキン，ジュリー
アンブラール－コーシル，ミュリエル
ラコムド，ギヨーム
ジャルバル－シャロワン，サビーヌ
シャヴァニュー，アラン
ブルゲ，ウィリアム
デルフォッセ，ヴァネッサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Original Assignee
Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Nationale Superieure de Chimie de Montpellier ENSCM filed Critical Ecole Nationale Superieure de Chimie de Montpellier ENSCM
Publication of JP2024519536A publication Critical patent/JP2024519536A/ja
Publication of JP2024519536A5 publication Critical patent/JP2024519536A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2023572137A 2021-05-19 2022-05-18 Ｐｘｒを標的とする二官能性ｐｒｏｔａｃ型化合物、同化合物を調製するための方法、及びその治療的使用 Pending JP2024519536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR2105217 2021-05-19
FR2105217A FR3122989B1 (fr) 2021-05-19 2021-05-19 Nouveaux composes bifonctionnels de type protac ciblant pxr, leur procede de preparation et leur utilisation en therapeutique
PCT/EP2022/063422 WO2022243365A1 (fr) 2021-05-19 2022-05-18 Composés bifonctionnels de type protac ciblant pxr, leur procédé de préparation et leur utilisation en thérapeutique

Publications (2)

Publication Number Publication Date
JP2024519536A true JP2024519536A (ja) 2024-05-15
JP2024519536A5 JP2024519536A5 (https=) 2025-06-02

Family

ID=76284058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572137A Pending JP2024519536A (ja) 2021-05-19 2022-05-18 Ｐｘｒを標的とする二官能性ｐｒｏｔａｃ型化合物、同化合物を調製するための方法、及びその治療的使用

Country Status (7)

Country Link
US (1) US20240252658A1 (https=)
EP (1) EP4340887A1 (https=)
JP (1) JP2024519536A (https=)
CN (1) CN117295523A (https=)
CA (1) CA3218875A1 (https=)
FR (1) FR3122989B1 (https=)
WO (1) WO2022243365A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118344284A (zh) * 2024-03-06 2024-07-16 杭州医学院 一种具有苯甲酰胺结构的化合物及其制备方法和应用
CN121735909A (zh) * 2024-09-27 2026-03-27 上海交通大学医学院附属瑞金医院 多价分子胶类化合物及其制备和应用
US20260092058A1 (en) 2024-09-30 2026-04-02 St. Jude Children's Research Hospital, Inc. Small Molecule Degraders and Fluorescent Probes of PXR

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017223415A1 (en) * 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ADVANCED THERAPEUTICS, vol. 3, no. 11, JPN5025002479, 2020, pages 1 - 21, ISSN: 0005766066 *
MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 485, JPN5025002480, 2019, pages 61 - 71, ISSN: 0005766067 *
SIGNAL TRANSDUCTION AND TARGETED THERAPY, vol. 4, no. 1, JPN5025002478, 2019, pages 1 - 33, ISSN: 0005766068 *

Also Published As

Publication number Publication date
CN117295523A (zh) 2023-12-26
US20240252658A1 (en) 2024-08-01
FR3122989B1 (fr) 2024-03-29
EP4340887A1 (fr) 2024-03-27
FR3122989A1 (fr) 2022-11-25
WO2022243365A1 (fr) 2022-11-24
CA3218875A1 (fr) 2022-11-24

Similar Documents

Publication Publication Date Title
JP6970802B2 (ja) 二官能性分子によって標的化タンパク質分解を誘導する方法
JP7320263B2 (ja) Ｅｚｈ２阻害剤及びその使用
EP3184519B1 (en) Acid-addition salt of trk-inhibiting compound
JP6042157B2 (ja) 変異型ｃ−ｋｉｔの阻害方法
JP2024519536A (ja) Ｐｘｒを標的とする二官能性ｐｒｏｔａｃ型化合物、同化合物を調製するための方法、及びその治療的使用
JP5385268B2 (ja) インドリン−２−オンおよびアザ−インドリン−２−オン
JP2018511631A (ja) Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
WO2019170150A1 (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
JP2022504541A (ja) 低分子ｍｄｍ２タンパク質デグレーダー
JP2001516694A (ja) プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
CA3172987A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
TW201625620A (zh) 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法
EP3421472B1 (en) Aza-tryptanthrin derivatives as ido1 and/or tdo inhibitors
JP2015522048A (ja) 癌の処置および免疫抑制のための併用療法
CA3231240A1 (en) Ink4 tumor suppressor proteins mediate resistance to cdk4/6 kinase inhibitors
TWI546304B (zh) Protein tyrosine kinase inhibitors and their use
CN109293588A (zh) 一种具有ido1/tdo双靶点的小分子化合物及其制备方法与应用
US12497411B2 (en) Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia
WO2023122298A1 (en) Protein stabilizing compounds containing usp28 and/or usp25 targeting ligands
CN103906751A (zh) 作为晚期SV40因子（LSF）抑制剂用于治疗癌症的[1,3]二氧杂环戊烯并[4,5-g]喹啉-6(5H)-硫酮和[1,3]二氧杂环戊烯并[4,5-g][1,2,4]三唑并[1,5-a]喹啉衍生物
CN109081818A (zh) 新型吲哚胺2,3-双加氧化酶抑制剂
KR100874209B1 (ko) 3,10-다이하이드로-1Ｈ-[1,4]다이아제피노[5,6-ｂ]인돌-2-온 유도체 및 약학적으로 허용 가능한 염, 그의 제조방법및 그의 용도
CN118234498A (zh) Sting调节剂、组合物及其使用方法
WO2026050773A1 (en) Protein kinase inhibitors and uses thereof
WO2024174949A1 (zh) 作为cdk7激酶抑制剂的杂芳环化合物及其制备和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406